San Juan University Hospital, Alicante, Spain.
Miguel Hernández University of Elche, Alicante, Spain.
Int J Infect Dis. 2024 Jun;143:107018. doi: 10.1016/j.ijid.2024.107018. Epub 2024 Mar 22.
Human T-lymphotropic viruses (HTLV)-1 infection is endemic in many countries of Central and South America and Caribbean (CSA&C). Neither screening nor surveillance programs exist for HTLV-1/2 infection among pregnant women in this region. Neither in Western nations with large migrant flows from HTLV-1/2 endemic regions.
Systematic review and meta-analysis of the prevalence of HTLV-1/2 infection among CSA&C pregnant women. We included studies searching EMBASE, PubMed/MEDLINE, Scopus, and Web of Science from inception to February 15, 2023. This systematic review followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines.
We identified a total of 620 studies. Only 41 were finally included in the meta-analysis. Most studies (61.0%) were from Brazil and Peru (14.6%). The total number of participants was 343,707. The pooled prevalence of HTLV-1/2 infection among CSA&C pregnant women was 1.30% (95% CI: 0.96-1.69) using anti-HTLV-1/2 antibody screening tests. There was a high heterogeneity (I = 98.6%). Confirmatory tests gave an HTLV-1 infection rate of 1.02% (95% CI: 0.75-1.33).
The prevalence of HTLV-1/2 infection among CSA&C pregnant women is 1.3%, most cases being HTLV-1. This rate is greater than for other microbial agents regularly checked as part of antenatal screening (such as HIV, hepatitis B, or syphilis). Thus, HTLV-1/2 antenatal testing should be mandatory among CSA&C pregnant women everywhere.
人类 T 淋巴细胞病毒 (HTLV)-1 感染在中美洲和南美洲以及加勒比地区(CSA&C)的许多国家流行。该地区的孕妇既没有进行 HTLV-1/2 感染的筛查,也没有进行监测计划。在拥有大量来自 HTLV-1/2 流行地区移民的西方国家也是如此。
对 CSA&C 孕妇中 HTLV-1/2 感染的流行率进行系统回顾和荟萃分析。我们纳入了从成立到 2023 年 2 月 15 日在 EMBASE、PubMed/MEDLINE、Scopus 和 Web of Science 上搜索的研究。本系统评价遵循系统评价和荟萃分析报告的首选报告项目。
我们共检索到 620 项研究,最终仅有 41 项研究被纳入荟萃分析。大多数研究(61.0%)来自巴西和秘鲁(14.6%)。共有 343707 名参与者。使用抗 HTLV-1/2 抗体筛查试验,CSA&C 孕妇中 HTLV-1/2 感染的总流行率为 1.30%(95%CI:0.96-1.69)。存在高度异质性(I = 98.6%)。确认试验得出 HTLV-1 感染率为 1.02%(95%CI:0.75-1.33)。
CSA&C 孕妇中 HTLV-1/2 感染的流行率为 1.3%,大多数病例为 HTLV-1。这一比率高于其他作为常规产前筛查一部分检查的微生物病原体(如 HIV、乙型肝炎或梅毒)。因此,HTLV-1/2 产前检测应成为 CSA&C 孕妇的强制性检测。